Terms: = Prostate cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
39 results:
1. The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
Hu C; Qiao X; Hu C; Cao C; Wang X; Bao J
Cancer Imaging; 2024 Feb; 24(1):23. PubMed ID: 38326860
[TBL] [Abstract] [Full Text] [Related]
2. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
3. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity of [
Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
[TBL] [Abstract] [Full Text] [Related]
5. Fast cross-staining alignment of gigapixel whole slide images with application to prostate cancer and breast cancer analysis.
Wang CW; Lee YC; Khalil MA; Lin KY; Yu CP; Lien HC
Sci Rep; 2022 Jul; 12(1):11623. PubMed ID: 35803996
[TBL] [Abstract] [Full Text] [Related]
6. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
7. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis.
Sheng M; Guo S; Liu C
World J Surg Oncol; 2021 Dec; 19(1):345. PubMed ID: 34903228
[TBL] [Abstract] [Full Text] [Related]
8. Predictive factors of tumor sink effect: Insights from
Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
[TBL] [Abstract] [Full Text] [Related]
9. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract] [Full Text] [Related]
10. IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer Eradication in a preclinical model.
Wang D; Shao Y; Zhang X; Lu G; Liu B
J Transl Med; 2020 Jan; 18(1):23. PubMed ID: 31937346
[TBL] [Abstract] [Full Text] [Related]
11. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.
Xie GS; Li G; Li Y; Pu JX; Huang YH; Li JH; Yin HM
Chin Med J (Engl); 2019 Nov; 132(22):2684-2689. PubMed ID: 31725446
[TBL] [Abstract] [Full Text] [Related]
12. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic prostate cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract] [Full Text] [Related]
13. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract] [Full Text] [Related]
14. The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review).
Ullah K; Addai Peprah F; Yu F; Shi H
Oncol Rep; 2018 Dec; 40(6):3136-3143. PubMed ID: 30542701
[TBL] [Abstract] [Full Text] [Related]
15. Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes.
Moroz MA; Zanzonico P; Lee JT; Ponomarev V
Methods Mol Biol; 2018; 1790():153-163. PubMed ID: 29858790
[TBL] [Abstract] [Full Text] [Related]
16. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
[TBL] [Abstract] [Full Text] [Related]
17. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After prostatectomy for prostate cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract] [Full Text] [Related]
18. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer.
Wu X; Reinikainen P; Vanhanen A; Kapanen M; Vierikko T; Ryymin P; Hyödynmaa S; Kellokumpu-Lehtinen PL
Diagn Interv Imaging; 2017 Jan; 98(1):63-71. PubMed ID: 27687831
[TBL] [Abstract] [Full Text] [Related]
19. Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the prostate cancer Registry.
Daniels CP; Millar JL; Spelman T; Sengupta S; Evans SM
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):247-54. PubMed ID: 26548940
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
[TBL] [Abstract] [Full Text] [Related]
[Next]
